432 related articles for article (PubMed ID: 32803520)
1. Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy.
Gentzler RD; Riley DO; Martin LW
Curr Oncol Rep; 2020 Aug; 22(11):109. PubMed ID: 32803520
[TBL] [Abstract][Full Text] [Related]
2. [Preliminary Efficacy Evaluation of Neoadjuvant Immunotherapy Combined with
Chemotherapy in Resectable Non-small Cell Lung Cancer].
Zhou S; Hao X; Yu D; Liu S; Cao X; Su C; Song X; Xiao N; Li Y; Yang W; Zhao D; Wang J; Liu Z; Xu S
Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):420-425. PubMed ID: 34024062
[TBL] [Abstract][Full Text] [Related]
3. The emerging perioperative treatment paradigm for non-small cell lung cancer: a narrative review.
Christopoulos P
Chin Clin Oncol; 2024 Feb; 13(1):12. PubMed ID: 38372058
[TBL] [Abstract][Full Text] [Related]
4. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.
Liu X; Xing H; Liu H; Chen J
Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893
[TBL] [Abstract][Full Text] [Related]
5. Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer.
Parekh J; Parikh K; Reuss JE; Friedlaender A; Addeo A
Curr Oncol Rep; 2023 Aug; 25(8):913-922. PubMed ID: 37249833
[TBL] [Abstract][Full Text] [Related]
6. Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer.
Shen J; Gu L; Qi Y; Yao Y; Lu S; Chen Z
Front Immunol; 2023; 14():1268251. PubMed ID: 37818382
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant and Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer.
Broderick SR
Thorac Surg Clin; 2020 May; 30(2):215-220. PubMed ID: 32327180
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in patients with early stage resectable nonsmall cell lung cancer.
Ghysen K; Vansteenkiste J
Curr Opin Oncol; 2019 Jan; 31(1):13-17. PubMed ID: 30325753
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
10. Integrated management of stage III in nonsmall cell lung cancer: where do perioperative chemotherapy and immunotherapy fit?
Collazo-Lorduy A; Blanco M; Calvo V; Provencio M
Curr Opin Pulm Med; 2024 Jul; 30(4):346-351. PubMed ID: 38712693
[TBL] [Abstract][Full Text] [Related]
11. [Progress in Neoadjuvant Immunotherapies for Resectable Non-small Cell Lung Cancer].
Wang S; Mao Y
Zhongguo Fei Ai Za Zhi; 2020 May; 23(5):371-380. PubMed ID: 32283581
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant immunotherapy in nonsmall cell lung cancer.
Pall G
Curr Opin Oncol; 2021 Jan; 33(1):59-63. PubMed ID: 33229874
[TBL] [Abstract][Full Text] [Related]
13. Meta-Analysis of Neoadjuvant Immunotherapy for Patients with Resectable Non-Small Cell Lung Cancer.
Cao C; Le A; Bott M; Yang CJ; Gossot D; Melfi F; Tian DH; Guo A
Curr Oncol; 2021 Nov; 28(6):4686-4701. PubMed ID: 34898553
[TBL] [Abstract][Full Text] [Related]
14. Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.
Lee JM; Tsuboi M; Brunelli A
Ann Thorac Surg; 2022 Oct; 114(4):1505-1515. PubMed ID: 34339672
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis.
Jia XH; Xu H; Geng LY; Jiao M; Wang WJ; Jiang LL; Guo H
Lung Cancer; 2020 Sep; 147():143-153. PubMed ID: 32717571
[TBL] [Abstract][Full Text] [Related]
16. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer.
Bott MJ; Yang SC; Park BJ; Adusumilli PS; Rusch VW; Isbell JM; Downey RJ; Brahmer JR; Battafarano R; Bush E; Chaft J; Forde PM; Jones DR; Broderick SR
J Thorac Cardiovasc Surg; 2019 Jul; 158(1):269-276. PubMed ID: 30718052
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement.
Tieu BH; Sanborn RE; Thomas CR
Thorac Surg Clin; 2008 Nov; 18(4):403-15. PubMed ID: 19086609
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.
Ulas EB; Dickhoff C; Schneiders FL; Senan S; Bahce I
ESMO Open; 2021 Oct; 6(5):100244. PubMed ID: 34479033
[TBL] [Abstract][Full Text] [Related]
19. Moving Immunotherapy Into Early-Stage Lung Cancer.
Linehan A; Forde PM
Cancer J; 2020; 26(6):543-547. PubMed ID: 33298726
[TBL] [Abstract][Full Text] [Related]
20. The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer.
Jiang L; Huang J; Jiang S; Rong W; Shen Y; Li C; Tian Y; Ning J; Chen X; Yang Y; Ding Z; Li Z; Luo Q
Cancer Immunol Immunother; 2021 Aug; 70(8):2313-2321. PubMed ID: 33512555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
